Description
Non-Fucosylated Anti-Human LAG-3 (AGEN1746) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced LAG-3 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
LAG3
Full Name
Lymphocyte-activation gene 3
Background
Lymphocyte-activation gene 3, also known as LAG-3, is a protein which in humans is encoded by the LAG3 gene. LAG3, which was discovered in 1990 and was designated CD223 (cluster of differentiation 223) after the Seventh Human Leucocyte Differentiation Antigen Workshop in 2000, is a cell surface molecule with diverse biologic effects on T cell function. It is an immune checkpoint receptor and as such is the target of various drug development programs by pharmaceutical companies seeking to develop new treatments for cancer and autoimmune disorders. In soluble form it is also being developed as a cancer drug in its own right.
Alternative Names
LAG3, CD223, lymphocyte activating 3
Gene ID
Human: 3902; Mouse: 16768
UniProt ID
Human: P18627; Mouse: Q61790
Cellular Localization
Extracellular region or secreted; Plasma Membrane
Genecards
LAG3
Involvement in Disease
Diseases associated with LAG3 include Smoldering Myeloma and Kyphoscoliotic Heart Disease. Among its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Function
The main ligand of LAG3 is MHC class II, which has a higher binding force with CD4. [14] This protein negatively regulates cell proliferation, activation [15] and homeostasis of T cells in a similar manner to CTLA-4 and PD-1 [16] [17], and is reported to play a role in Treg inhibitory function. 18]
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
AGEN1746
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
